California Paid Clinical Trials

A listing of 5602 clinical trials in California actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Clinical Trials

California

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Location

Filter by Age

California is currently home to 5602 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

Featured Trial

Chronic Kidney Disease (CKD) Clinical Study

Recruiting

A clinical study for people that suffer with Chronic Kidney Disease (CKD)

Conditions:

Chronic Kidney Disease (CKD)

Learn More

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748

Recruiting

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/21/2025

Locations: Sutter Auburn Faith Hospital, Auburn, California

Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Learn More ›

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617

Recruiting

To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/21/2025

Locations: OM Research LLC, Lancaster, California

Conditions: Primary Biliary Cholangitis

Learn More ›

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

NCT05999994

Recruiting

The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.

Gender:

ALL

Ages:

Between 1 year and 39 years

Trial Updated:

08/21/2025

Locations: Childrens Hospital of Los Angeles, Los Angeles, California

Conditions: Neoplasms, Child, Adolescent

Learn More ›

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182

Recruiting

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This study will assess how safe and effective upadacitinib is in treating adult and adolescent participants with moderate to severe HS who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy. Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for ulcerative colitis, atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of HS. This study is "double-blinded", meaning that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo. This study is comprised of 3 periods. In Period 1, participants are randomized into 2 groups called treatment arms where each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. In Period 2, participants are placed into 6 different groups depending on their placement and results in Period 1. Period 3 is the long-term extension period where participants will continue treatment from Period 2. Approximately 1328 adult and adolescent participants diagnosed with HS will be enrolled in approximately 300 sites worldwide. Participants will receive oral tablets of upadacitinib or placebo once daily for 36 weeks in Period 1 and Period 2. Eligible participants from Period 1 and Period 2 will enter Period 3 and receive oral tablets of upadacitinib or placebo once daily for 68 weeks. Participants will be followed up for approximately 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular outpatient visits during the study. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires. Read Less

Gender:

ALL

Ages:

12 years and above

Trial Updated:

08/21/2025

Locations: Private Practice - Dr. Tooraj Raoof /ID# 254374, Encino, California

Conditions: Hidradenitis Suppurativa

Learn More ›

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643

Recruiting

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double... Read More

Gender:

ALL

Ages:

Between 18 years and 63 years

Trial Updated:

08/21/2025

Locations: Kaiser Permanente Lakeview Medical Offices /ID# 253906, Anaheim, California

Conditions: Systemic Lupus Erythematosus

Learn More ›

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

NCT05828069

Recruiting

This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form... Read More

Gender:

ALL

Ages:

Between 180 days and 22 years

Trial Updated:

08/21/2025

Locations: Kaiser Permanente Downey Medical Center, Downey, California

Conditions: Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis

Learn More ›

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

NCT05784246

Recruiting

The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).

Gender:

ALL

Ages:

Between 2 years and 17 years

Trial Updated:

08/21/2025

Locations: Stanford University, Palo Alto, California

Conditions: Ulcerative Colitis

Learn More ›

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

NCT05739942

Recruiting

This study will investigate different doses of \[177Lu\]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of \[177Lu\]Lu-NeoB in combination with the SoC and in recurrent glioblastoma as single agent, to identify the recommended dose and to also explore the safety of the PET imaging agent \[68Ga\]Ga-NeoB and characterize its uptake in the tumor area.

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

08/21/2025

Locations: University of California LA, Los Angeles, California

Conditions: Newly Diagnosed and Recurrent Glioblastoma

Learn More ›

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

NCT05734105

Recruiting

This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or di... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/21/2025

Locations: UC San Diego Moores Cancer Center, La Jolla, California

Conditions: GIST

Learn More ›

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

NCT05711615

Recruiting

This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells.... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/21/2025

Locations: Los Angeles General Medical Center, Los Angeles, California

Conditions: Metastatic Leiomyosarcoma, Metastatic Sarcoma, Unresectable Leiomyosarcoma, Unresectable Sarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Myxofibrosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Myxofibrosarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma

Learn More ›

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05600777

Recruiting

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

08/21/2025

Locations: GSK Investigational Site, Los Angeles, California

Conditions: Refractory Chronic Cough, Cough

Learn More ›

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

NCT05599984

Recruiting

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy and in combination with budigalimab, carboplatin, or cisplatin. ABBV-706 is an investigational drug being developed for the treatment of small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine carcinomas (NECs). There are multiple treatment arms in this study. Participants will either receive ABBV-706 as a single agent or in combination with budigalimab (another investigational drug), carboplatin or cisplatin at different doses. Approximately 350 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), ABBV-706 will be intravenously infused in escalating doses as a monotherapy until the maximum tolerated dose (MTD) is determined in participants with SCLC, high-grade CNS tumors, and high-grade NECs. In part 2, multiple doses will be selected from Part 1 and SCLC participants will be assigned to one of these doses in a randomized fashion to determine the recommended Phase 2 dose. In Part 3a, participants with SCLC or NECs will receive ABBV-706 in combination with budigalimab intravenously every 3 weeks. In Part 3b participants with SCLC or NECs will receive ABBV-706 in combination with either carboplatin or cisplatin intravenously. In Part 4a, participants with CNS tumors will receive ABBV-706 intravenously at a dose determined from Part 1. In Part 4b, participants with NECs will receive ABBV-706 intravenously at a dose selected from Part 1. The estimated duration of the study is up to 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/21/2025

Locations: City Of Hope Comprehensive Cancer Center /ID# 271295, Duarte, California

Conditions: Advanced Solid Tumors

Learn More ›

Kaiser Permanente houses over 6,000 physicians in southern California and it is also one of the largest research centers on the state. On its clinical trial division, Kaiser Permanente conducts clinical trials of almost every specialty funded by pharmaceutical companies, government, and foundations.

The Cedars-Sinai Medical Center located in Los Angeles is one of the largest research centers owned and operated by a private hospital in the United States. Focusing on biomedical, cancer, and heart research among other specialties, you can find almost any type of clinical trials for both health and non-healthy volunteers at the research division of Cedar-Sinai Medical Center.

There are around 100,000 clinical trials happening every year across the United States about almost every condition out there. While most clinical trials are testing drugs or medical devices there are also many behavioral and observational trials going on at any point in time. Many paid research studies are held at these California locations.

Clinical trials are incredibly important for making new medical and scientific discoveries, finding new and better methods for diagnosing medical conditions early, testing new interventions, and even developing safer and more effective surgical procedures.

In order for all these discoveries to me made available to the general population they need to go through years of rigorous testing both in healthy and non-healthy volunteers. During those years, medical professionals follow a protocol that has been previously approved by the FDA or other regulatory agency to test the effectiveness and safety of their discovery.

Other people choose to participate in a clinical trial because they feel it is a good way to contribute to the advancement of medical knowledge and that their participation can help many people in the future. The following lists of trials are broken down by condition, and to find a specific clinical trial in your area click through to clinicaltrials.gov.